About Osiris
Osiris is a company based in Baltimore (United States) founded in 1992 was acquired by Smith & Nephew in March 2019. The company has 356 employees as of December 31, 2018. Osiris operates in a competitive market with competitors including Horizon Therapeutics, Histogenics, Mesoblast, Osteal Therapeutics and Enobia Pharma, among others.
- Headquarter Baltimore, United States
- Employees 356 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Osiris Therapeutics, Inc.
-
Annual Revenue
$142.82 M (USD)21as on Dec 31, 2018
-
Net Profit
-
EBITDA
$9.85 M (USD)595as on Dec 31, 2018
-
Latest Funding Round
- Investors
-
Employee Count
356
as on Dec 31, 2018
-
Acquired by
Smith & Nephew
(Mar 12, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Osiris
Unlock access to complete
Funding Insights of Osiris
Investors in Osiris
Osiris has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Smith & Nephew.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer of knee, hip and shoulder joint replacements
|
Founded Year | Domain | Location |
Investments & Acquisitions by Osiris
Financial Statements - Osiris
Osiris Comparisons
Competitors of Osiris
Osiris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, Histogenics, Mesoblast, Osteal Therapeutics and Enobia Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Restorative cell therapies for orthopedic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Biotherapeutics derived from proprietary adult stem cell-based technologies
|
|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections
|
|
| domain | founded_year | HQ Location |
Therapies for genetic metabolic bone disorders are developed.
|
|
| domain | founded_year | HQ Location |
Cellular therapeutics are developed for cancer, orthopaedics, and COPD.
|
Frequently Asked Questions about Osiris
Osiris was founded in 1992.
Osiris is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
As of Dec 31, 2018, the latest employee count at Osiris is 356.
Annual revenue of Osiris is $142.82M as on Dec 31, 2018.
Osiris Therapeutics was founded in 1992 in Baltimore, United States, based on stem cell technology from Case Western Reserve University. Operations focus on biotechnology within regenerative medicine, including bioengineering and viable tissue products. Commercial products such as BIO4, Cartiform, and Grafix are provided for orthopaedics, sports medicine, and wound care. Research and development continue to advance stem cell applications.
Osiris's top competitors include Horizon Therapeutics, RoosterBio and Mesoblast.
Osiris has 1 investor. Key investors include Smith & Nephew.